Home/ Crypto News/ SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress
blockonomi Aug 24, 2026

SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress

Stocks

SELLAS Life Sciences (SLS) stock soars 255% YTD as Phase 3 AML trial hits critical milestone. Analysts set $10 target amid rising institutional interest.

The post SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 Leukemia Trial Progress appeared first on Blockonomi.

Source: Source: Blockonomi

Related News

Trending Category

200-day moving average 24/7 trading 4-Year Cycle AAP Stock AB 2409 AI AI Agents AI Data Centers AI IPO market AI Infrastructure AI Stocks AI automation AI backlash AI capital rotation AI spending AI trading AMD Stock AML AML compliance AMM Liquidity Pools

Latest News

Exchange Here